Under: Weight Loss
Best Peptides for BPC-157 and GLP-1 Medications — Gut Health & Recovery
BPC-157 is a research peptide studied for gut healing and gastroprotection. Some users combine it with GLP-1 medications to address GI side effects, though no clinical trials have studied this combination.
BPC-157 (Body Protection Compound-157) is a pentadecapeptide derived from human gastric juice that has shown gastroprotective, anti-inflammatory, and wound-healing properties in preclinical studies. In animal models, BPC-157 has demonstrated protection against gastric ulcers, acceleration of gut mucosal healing, and modulation of the NO and dopamine systems involved in GI motility. This has led to interest in the GLP-1 community about using BPC-157 to mitigate the GI side effects (nausea, gastroparesis, gut inflammation) caused by GLP-1 receptor agonists. However, no human clinical trials have studied BPC-157 in combination with GLP-1 medications. BPC-157 is not FDA-approved for any use. Users considering this combination should discuss it with their healthcare provider.
BPC-157 is typically researched at 200-500 mcg/day via subcutaneous injection. There is no established protocol for combining it with GLP-1 therapy. This is an area of preclinical research, not clinical practice.
Peptides Studied for BPC-157 and GLP-1 Medications — Gut Health & Recovery
| Peptide | Evidence | Notes | Actions |
|---|---|---|---|
| Semaglutide Semaglutide is a GLP-1 receptor agonist — a 31-amino acid peptide analog of human glucagon-like peptide-1 (GLP-1) with a 94% sequence homology to native GLP-1. It is FDA-approved for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy). Semaglutide has an albumin-binding fatty acid side chain that extends its half-life to approximately 7 days, enabling once-weekly dosing. It is the most widely prescribed GLP-1 medication globally, with over 25 million Americans expected to be on GLP-1 therapy by 2030. | low | No clinical data on BPC-157 + semaglutide. Community interest driven by GI side effect management. | |
| Tirzepatide Tirzepatide is the first dual GIP/GLP-1 receptor agonist — a 39-amino acid synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors. FDA-approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). In clinical trials, tirzepatide demonstrated greater weight loss than semaglutide, with up to 22.5% body weight reduction at the highest dose. | low | Same rationale as semaglutide — theoretical GI benefit from BPC-157 gastroprotection. |
Semaglutide is a GLP-1 receptor agonist — a 31-amino acid peptide analog of human glucagon-like peptide-1 (GLP-1) with a 94% sequence homology to native GLP-1. It is FDA-approved for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy). Semaglutide has an albumin-binding fatty acid side chain that extends its half-life to approximately 7 days, enabling once-weekly dosing. It is the most widely prescribed GLP-1 medication globally, with over 25 million Americans expected to be on GLP-1 therapy by 2030.
No clinical data on BPC-157 + semaglutide. Community interest driven by GI side effect management.
Tirzepatide is the first dual GIP/GLP-1 receptor agonist — a 39-amino acid synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors. FDA-approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). In clinical trials, tirzepatide demonstrated greater weight loss than semaglutide, with up to 22.5% body weight reduction at the highest dose.
Same rationale as semaglutide — theoretical GI benefit from BPC-157 gastroprotection.